What we said:
Read Biense Visser's LinkedIn bio. Ran a pharma company and sold it to Teva. Then ran a seed company and sold it to Monsanto. AAP is next. . . . Distributors tell us LOQTEQ superior to orthopedic devices offered by Stryker and Johnson & Johnson.
What happened: From our purchase price of €1.30, AAQ shares doubled. Sell-side research analysts are beginning to take note of LOQTEQ sales potential.